LILRB4 and non-small cell lung carcinoma: LILRB4 is highly expressed on MDSCs of patients with NSCLC, correlating with poor OS due to the immunosuppressive environment and the enhanced migration, invasion and pro-angiogenic ability of NSCLC cells by binding to APOE (195, 196).